

## **Antibiotic Resistance Crisis**

- Antibiotic Resistant (AR) infections represent a global health crisis, as nearly 50% of prescribed antibiotics prove ineffective
- In the US, antibiotic resistant bacteria are responsible for 2 million infections annually, and draw \$20 billion in treatment costs and novel drug development (Figure 1)



• In 2013, the CDC declared Acinetobacter baumannii as one of the ESKAPE Pathogens

## **Research Objective**

- Develop a bacteriophage-based therapeutic cocktail as an alternative treatment against antibiotic-resistant infections
- Compare bacteriophage therapeutics to conventional treatments and determine synergistic effects with antibiotics

## **Bacteriophage Therapeutics**

• Bacteriophages are a type of virus that exclusively infect bacteria. They are extremely abundant, with an estimated 10<sup>32</sup> total virus particles. The mechanism of action is summarized in *Figure 2* 



- Figure 2. Bacteriophage structure and Lytic Cycle summary
- Phage therapy is a promising yet insufficiently researched tool for solving the antibiotic resistance crisis. Phage therapeutics offer the following advantages:
- Coevolution allows phage to target resistant bacteria
- Lower rate of toxicity caused by release of endotoxins
- Penetration of biofilms in medical and food safety settings
- Phage cocktails, or mixtures, enhance treatment effectiveness

# Therapeutic Use of Bacteriophage Cocktails for the Treatment of **Antibiotic Resistant Acinetobacter baumannii Infections**

Kierstin Acuña, Mariama Barrie, Madeline Beaudry, Rory Cooley, Colin Fields, Spencer Grissom, Zachery Keepers, Anna Lavrentieva,

Hannah Sutton, Timothy Walsh, and Natalie Wittick



Figure 3. Growth curves for five strains of AR A. baumannii executed in a 24 well microplate reader. The bacteria overshoot the carrying capacity of the flask and a correction is observed at hours post-inoculation to achieve stationary phase.



## 1) B<sub>o</sub>Culture 2 $B_1$ and $B_2$ Co-Culture 3) Steps 1 and 2 repeated

process, a library of bacteriophages is generated.

Figure 5. Reduction of bacterial optical density is preceded by a surge in phage titer. Mid-log cultures of *E. coli*-pGlo were inoculated with phage at an MOI of 0.5 PFU/CFU. A background phage titer of ~8.5 PFU/mL corresponds to infected bacteria which were plated during titering. Reabsorption of phages to the remaining viable bacteria was observed after the initial burst.



University of Maryland Honors College Gemstone Honors Program



Figure 7. I shows phage plaques Figure 6. Growth curve for *A. baumannii* while II shows no plaques indicating showing greater lag periods as the the absence of phage. III shows infection (MOI) multiplicity of phage resistant colonies. IV shows increased. Uninfected bacteria showed individual plaques. far less lag in growth than all MOIs.



**Figure 8.** Bactericidal action of  $\lambda$ -mut **Figure 9.**  $\lambda$ -mut titer increase before phage a decrease in optical density is dependence shows on concentration. Mid-log cultures of E. observed. At 30 minutes post *coli*-pGlo were infected with the indicated inoculation the phage titer in each dilution of  $\lambda$ -mut stock. The optical density flask increases by slightly more than of infected flasks decreased significantly 2 log units and increased by a 45 minutes post infection. The undiluted further 4 units after 60 minutes. flask was completely lysed at this time.

## **Future Research Goals**

Prove viability of coevolution using *A. baumannii* and *E. coli*: • Phages in conjunction with antibiotics--show that bacteria treated with phages become susceptible to non-harmful antibiotic treatments • Parasitic bacterium--Bdellovibrio bacteriovorus is a bacteria that attacks other gram-negative bacteria • Expansive phage library--show that with more phages evolved there is

- greater effectiveness against bacteria

## **Acknowledgements and Citations**

We would would like to thank Dr. Frank Coale, Dr. Kristen Skendall, Ms. Vickie Hill, Dr. Daniel Nelson, and the Gemstone Honors Program for supporting this research and our mentor Mr. Kevin Knapstein and the University of Maryland Bioprocess Scale-Up Facility for continued guidance and laboratory space. Facility for continued guidance and laboratory space.







### Results



![](_page_0_Figure_49.jpeg)

![](_page_0_Picture_51.jpeg)